Total Synthesis of Ledipasvir (Harvoni®)

J. Med. Chem. **2014**, *57*, 2033-2046. Bioorg. Med. Chem. **2016**, *24*, 1937-1980.

- Ledipasvir is a potent NS5A inhibitor that is approved for use in combination with sofosbuvir, a nucleotide inhibitor of viral polymerase, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection
- The combination was discovered and developed at Gilead Sciences and is marketed as the fixed combination with brand name of Harvoni®.





Retro-synthetic Analysis

HO OH
$$\frac{I_2$$
, PPh₃, imidazole I_2 , PPh₃

2) (1S, 2R)-amino-indanol 2-MeTHF, rt, 33%

135

Boc

···CO₂H

131

132

134

1) 1 M HCI, 2-MeTHF, rt, 100% 2) t-BuOK, 2-MeTHF, 40 °C, 86% 136

$$PPh_3 + I_2 \longrightarrow PPh_3 + I \bigcirc HO R R O - PPh_3 - O - PPh_3 R I$$

$$132$$

Ar'-BPin

Oxalic acid is used for forming salt.

$$R_{2}N^{-Boc} \equiv R_{2}N^{\oplus}O \xrightarrow{H} R_{2}N^{\ominus}O \xrightarrow{-H^{\oplus}} R_{2}N^{\ominus$$